Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment-Reference-Cited by-同舟云学术

Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment

Published:2011-04 Issue:2 Volume:23 Page:286-292
ISSN:0952-7915
Container-title:Current Opinion in Immunology
language:en
Short-container-title:Current Opinion in Immunology

Author:

Gajewski Thomas F,Fuertes Mercedes,Spaapen Robbert,Zheng Yan,Kline Justin

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference46 articles.

1. Chemokines expressed in melanoma metastases associated with T cell infiltration;Gajewski;Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I,2007

2. Association of gene expression profile in melanoma and survival to a dendritic cell-based vaccine;Gajewski;J Clin Oncol,2009

3. Expression of defined genes identified by pre-treatment tumor profiling: association with clinical responses to the GSK MAGE-A3 immunotherapeutic in metastatic melanoma patients;Louahed;J Clin Oncol,2008

4. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy;Gajewski;Cancer J,2010

5. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment;Harlin;Cancer Res,2009

Cited by 130 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The roles of genetic mutation and cytokines/chemokines in immune response and their association with uveal melanoma patient outcome;Heliyon;2024-09

2. Targeting the Atypical Chemokine Receptor 2 (ACKR2) improves the benefit of anti-PD-1 immunotherapy in melanoma;2024-04-03

3. The Roles of Genetic Mutation and Cytokines/Chemokines in Immune Response and Their Association with Uveal Melanoma Patient Outcome;2024

4. Safety and efficacy of immune checkpoint inhibitors after allogeneic hematopoietic cell transplantation;Bone Marrow Transplantation;2023-07-29

5. BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti‐PD‐1/PD‐L1 Immunotherapy by Negatively Regulating Proinflammatory Chemokines and Anticancer Immunity;Advanced Science;2023-01-15